← Back to all trials
Active Not Recruiting
NCT06921850
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Conditions: Hidradenitis Suppurativa
Sex: All
Ages: 9 Years – 17 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 43
Sponsor: UCB Biopharma SRL
Location: Hs0006 50175 Phoenix Arizona
Summary
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Eligibility Criteria
Inclusion Criteria:
* Study participant must be 12 to \
Source: ClinicalTrials.gov (NCT06921850). StuddyBuddy aggregates publicly available trial information.
